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Abstract
Background: We applied a non-linear immunokinetic model to quantitatively compare absolute antibody uptake and
turnover in subcutaneous LNCaP human prostate cancer (PCa) xenografts of two radiolabeled forms of the humanized
anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (124I-J591 and 89Zr-J591). Using the model,
we examined the impact of dose on the tumor and plasma positron emission tomography (PET)-derived time-activity
curves. We also sought to predict the optimal targeting index (ratio of integrated-tumor-to-integrated-plasma activity
concentrations) for radioimmunotherapy.
Methods: The equilibrium rates of antibody internalization and turnover in the tumors were derived from PET images
up to 96 h post-injection using compartmental modeling with a non-linear transfer rate. In addition, we serially imaged
groups of LNCaP tumor-bearing mice injected with 89Zr-J591 antibody doses ranging from antigen subsaturating to
saturating to examine the suitability of using a non-linear approach and derived the time-integrated concentration
(in μM∙hours) of administered tracer in tumor as a function of the administered dose of antibody.
Results: The comparison of 124I-J591 and 89Zr-J591 yielded similar model-derived values of the total antigen
concentration and internalization rate. The association equilibrium constant (ka) was twofold higher for
124I, but there was
a ~tenfold greater tumoral efflux rate of 124I from tumor compared to that of 89Zr. Plots of surface-bound and internalized
radiotracers indicate similar behavior up to 24 h p.i. for both 124I-J591 and 89Zr-J591, with the effect of differential
clearance rates becoming apparent after about 35 h p.i. Estimates of J591/PSMA complex turnover were 3.9–90.5 × 1012
(for doses from 60 to 240 μg) molecules per hour per gram of tumor (20 % of receptors internalized per hour).
Conclusions: Using quantitative compartmental model methods, surface binding and internalization rates were
shown to be similar for both 124I-J591 and 89Zr-J591 forms, as expected. The large difference in clearance rates of the
radioactivity from the tumor is likely due to differential trapping of residualizing zirconium versus non-residualizing
iodine. Our non-linear model was found to be superior to a conventional linear model. This finding and the calculated
activity persistence time in tumor have important implications for radioimmunotherapy and other antibody-based
therapies in patients.
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Background
Prostate-specific membrane antigen (PSMA) is an integral
cell membrane glycoprotein (~100 kDa) that is present on
the surface of epithelial prostate cancer (PCa) cells [1].
While PSMA is expressed in normal human prostate cells
and certain other normal tissues, it is highly upregulated
in PCa, making it a promising diagnostic and therapeutic
target [2]. A variety of monoclonal antibodies (mAbs) spe-
cific for intracellular and extracellular epitopes of PSMA
have been prepared [3–6], with two variants in particular
demonstrating high (low nM) affinity and specific and
efficient targeting in vivo: the murine mAb 7E11, which
binds an intracellular domain of PSMA, and the human-
ized mAb J591, which binds to an extracellular domain of
PSMA. 7E11 has been investigated clinically as a SPECT
imaging agent for recurrent and metastatic PCa [7]
(111In-7E11, ProstaScint™) as well as therapeutically as the
Y-90 conjugate [8]. Like 7E11, J591 has also been clinically
investigated in a variety of radiolabeled forms for both posi-
tron emission tomography (PET) imaging (e.g., in the form
of 89Zr-J591) [9] as well as therapy (e.g., as 177Lu-J591) [10].
When J591 binds to the external domain of PSMA on
LNCaP prostate cancer cells, the J591/PSMA complex
undergoes endocytosis via clathrin-coated pits and accu-
mulates in endosomes (3). Indeed, the surface binding and
subsequent internalization are the fundamental rationale
for using J591 as a carrier for residualizing radiometals and
cytotoxic drug conjugates [11–13] that rely on such intern-
alization to maximize their therapeutic effectiveness.
Quantitative imaging and kinetic analysis of a theranostic
agent allows for collection of patient-specific information
regarding optimization of a subsequently administered
radioimmunotherapeutic or antibody-drug conjugate.
This is an emerging paradigm recently demonstrated by
Zanzonico et al. in colorectal patients administered with
radiolabeled anti-A33 humanized mAb and undergoing
serial PET imaging and blood sampling [14]. Collectively,
such data can be used to derive estimates of radiation doses
or toxin concentrations in tumor and normal tissues to
assess the risk/benefit of a particular treatment as well as
to calculate an optimum mAb dose for the treatment. This
is a practical and important step towards a personalized
precision medicine approach: the tailoring of antibody-
vector dose to achieve the highest concentration at
antigen-positive sites while sparing normal tissue.
The effective implementation of a theranostic and/or a
companion diagnostic requires that the radiotracer, ideally,
should provide quantitative readouts of the antigen density
and other antigen-antibody binding parameters. This is
because therapeutic efficacy is, in part, correlated with
magnitude and duration of receptor occupancy by the
drug. To achieve this without interfering with subsequent
drug delivery, administration of subsaturating doses of
tracer can be used to estimate total receptor occupancy,
while accounting for differences in affinity between the
naked antibody and the antibody-conjugate (i.e., the
diagnostic and the therapeutic reagents, respectively).
In addition, initial estimates of other pertinent parameters
such as the antigen density per cell and the apparent
affinities of the naked antibody and antibody-conjugate
can be determined using standard in vitro assays.
The aim of this study was to examine the binding kin-
etics of J591 in a murine xenograft model of PCa using
quantitative PET and compartmental analysis of two
positron-emitting forms of this antibody radiolabeled
with either 89Zr or 124I. It is generally known that these
two isotopes have different fates following internalization.
The free radiometal 89Zr is trapped (or residualized) in the
cell while the free iodide generally exits the cell rather
quickly following such internalization of the antibody con-
struct [15–19]. These differences could have implications
for image quality and kinetics (e.g., see [20] for intra-
patient comparison of an anti-CAIX antibody radiolabeled
with either 131I or 111In).
Governed by the law of mass action, at higher mAb
doses, the amount of free antigen available for binding
may be decreased to such an extent that the association
rate of antibody is demonstrably affected [21]. To extrapo-
late high-dose antibody residence at the tumor from low-
dose estimates of binding parameters, the model must be
able to account for decreased concentration of available
antigen as a function of dose [22]. To this end, we intro-
duced a non-linear association term into the compartment
model to represent bimolecular antigen-antibody binding
kinetics (Fig. 1) [23]. This modification would be crucial
Fig. 1 Schematic diagram of the non-linear compartmental model
developed to represent saturable antibody kinetics. General notation:
k(a,b) indicates flow to compartment a from compartment b
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in planning and optimizing therapeutic doses based on
low-dose diagnostic data.
Methods
Reagents, antibodies, and cells
The humanized mAb J591 was kindly provided by Dr.
Neil Bander (Weill Medical College of Cornell University,
New York, NY). The PSMA-positive LNCaP cell line was
obtained from American Type Culture Collection and
maintained in culture by serial passage using standard
conditions: RPMI 1640 supplemented with 10 % FCS at
37 °C in an environment containing 5 % CO2. The antigen
density Bmax and dissociation equilibrium constant Kd
for J591 and intact (viable) LNCaP cells were previously
determined using in vitro saturation binding assays
and reported to be 600,000–800,000 sites/cell and
1.83 ± 1.21 nM, respectively [24].
Radiolabeled mAbs
The positron-emitting starting reagents [124I]NaI (t1/2 =
4.18 days) and [89Zr]Zr-oxalate (t1/2 = 3.17 days) were
provided by the Memorial Sloan Kettering Radiochemistry
& Molecular Imaging Probes Core Facility. Activity
measurements were made either with a dose calibrator
(Capintec) or an automated gamma counter (PerkinElmer
Wizard 3). For 89Zr radiolabeling, J591 was conjugated
with isothiocyanatobenzyl-desferrioxamine (SCN-DFO;
Macrocyclics, Dallas, TX) and subsequently radiolabeled
with 89Zr-oxalate as described [9] (specific activity (SA)
118 MBq/mg; radiolabeling efficiency (RE) 70 %; mini-
mum immunoreactivity (IR) 90 %). J591 was radiolabeled
with 124I as previously described [24] using the IODOGEN
method to a SA of 213 MBq/mg (RE 60 %; IR 75 %). The
radiochemical purity of each tracer was determined using
either instant thin-layer chromatography with 5 mM
DTPA pH 5.0 or 10 % trichloroacetic acid as the elution
solvent for 89Zr-mAb or 124I-mAb, respectively, and was
routinely >98 %. To prepare the different mAb mass
doses, non-radioactive J591 was added as necessary to
achieve the final desired mAb mass after drawing up the
89Zr-J591 [155-243 μCi (5.7–9.0 MBq) per animal] or
124I-J591 [171-267 μCi (6.3–9.9 MBq) per animal], based
on the initial SA of the respective preparations.
Xenograft model
All animal experiments were approved by the Institu-
tional Animal Care and Use Committee of Memorial
Sloan Kettering Cancer Center (MSKCC), and institu-
tional guidelines for the proper and humane use of ani-
mals in research were followed. Male athymic nude mice
(outbred, 4–6 weeks old) were obtained from Harlan
Laboratories (Indianapolis, IN) and allowed to acclimate
in the MSKCC vivarium for at least 1 week prior to
use. For tumor inoculation, cultured LNCaP cells were
trypsinized using a solution of 0.25 % trypsin/0.05 %
EDTA in Hank’s balanced salt solution without calcium or
magnesium and prepared for subcutaneous (s.c.) injection
in the lower flank as a suspension of five million cells
in a final volume of 200-μl volume as a 1:1 mixture
of reconstituted basement membrane (BD Matrigel,
Collaborative Biomedical Products) and media. Estab-
lished tumors (100–700 mm3) were observed in 4–6 weeks.
Tumors were measured using external vernier caliper
measurements and assumed to be spherical for calculation
of volume.
PET imaging studies
All radiolabeled antibodies were administered intraven-
ously (i.v.) via the tail vein into groups of mice (n = 2–5)
bearing s.c. LNCaP tumors at t = 0 after gentle warming
of each animal with a heat lamp. Prior to scanning,
animals were anesthetized using an inhaled mixture
of 1.5–2 % isofluorane (Baxter Healthcare, Deerfield,
IL) and air and placed on either the microPET Focus
120 (Concorde Microsystems, Knoxville, TN) or Inveon
PET/CT (Siemens Medical Solutions) small animal
scanner. No blocking with cold iodide was performed in
mice given 124I-J591.
For comparison of 89Zr- and 124I-J591, a total of four
groups were imaged. For imaging with 89Zr-J591, two
different mAb-carrier mass levels (expressed as micro-
grams of mAb) were studied: 60 (n = 3) or 180 (n = 2)
(0.4 and 1.2 nmol, respectively). For imaging with
124I-J591, groups were injected with either 45 (n = 5) or
180 (n = 2) (0.3 and 1.2 nmol, respectively). All groups
were imaged at least five time points from 4 to 96 h p.i.
For compartmental analysis of mAb-carrier dose escal-
ation with 89Zr-J591 as the tracer, additional imaging
studies were performed with five different dose levels
(micrograms of mAb): 58 (n = 4), 180 (n = 4), 240 (n = 4),
1000 (n = 5), and 2000 (n = 3) (0.39, 1.20, 1.60, 6.67, and
13.3 nmol, respectively). All groups were imaged at 24,
48, and 96 h p.i.
PET data were acquired using an energy window of
350–700 keV and a coincidence timing window of 6 ns.
The list mode data were sorted into two-dimensional
histograms by Fourier rebinning, and image reconstruc-
tion was performed by filtered back projection with a
128 × 128 × 63 (0.72 × 0.72 × 1.33 mm) matrix. The final
data were parameterized (as the percent of theinjected
dose per gram of tissue (%ID/g)) by first converting the
voxel-counting rates to activity concentrations using em-
pirically determined calibration factors for the specific iso-
tope, followed by decay correction to the time of injection
and normalization to the administered activity. No attenu-
ation or scatter was applied. Tumor and heart were manu-
ally delineated in 3D reconstructed images of each mouse,
and time-activity curves (TACs) were derived from the
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regions of interest (ROI) using ASIPro VM™ software
(Concorde Microsystems). TAC values were corrected
for partial volume effects based on tumor size. The heart
TAC was utilized as the blood input function for fully
quantitative kinetic modeling.
Compartmental modeling
A non-linear compartmental model was developed and
implemented using SAAM II modeling software (v. 1.1.1,
SAAM Institute, University of Washington, WA). This
model (Fig. 1) includes two tissue compartments and a
blood compartment representing the plasma input, q1.
The two tissue compartments modeled are the cell surface
binding compartment, q2, and an intracellular space
compartment where internalized antibody resides, q3.
Unidirectional flow is modeled among all three compart-
ments. The parameter k2,1 represents the flow from the
plasma compartment and binding to surface antigen. The
parameter k3,2 represents the passage of the antigen-
antibody (Ag-Ab) complex from the surface into the cell.
Finally, the fate of the radiolabel, whether sequestered in
the cell or removed from the tumor, is modeled by the
parameter, k0,3, which represents efflux from the intracel-
lular compartment and thus the tumor overall. Reverse
rates from the surface back to arterial plasma and from
the internalized compartment back to the surface are
excluded. These are based on the following assumptions:
(1) there is negligible dissociation of the antibody after
binding to the cell surface antigen; (2) once the Ag-Ab
complex has been internalized, it cannot be returned
to the surface in the intact radiolabeled form; and (3)
separation of the radiolabel from the Ag-Ab complex
only occurs after internalization.
Binding of radiolabeled antibody to surface antigen is
modeled as a non-linear saturable process given by the
equation for k2,1. This binding rate is dependent on the
concentrations of unbound and non-internalized antigen
present on the cell surface, specifically, the difference
([Agtotal] − [Ag-Ab]), where [Agtotal] represents the esti-
mated total antigen presented at the surface (i.e., Bmax)
and [Ag-Ab] represents the concentration of bound Ag-
Ab complex. The [Ag-Ab] value changes with time and
is derived from the measured tumor activity. The blood
component of the tumor activity is assumed to be 8 % of
the measured plasma activity. A similar model was pre-
viously described by Cheal et al. [23]. The input function
was measured directly from the serial PET images by
drawing an ROI over the heart (i.e., the left ventricle).
Starting values for the fitted parameters were derived
from in vitro data [24, 25]. Data points were Poisson-
weighted in fitting with SAAM II.
Model parameters derived from the low-dose 60 μg
89Zr-J591 TACs in combination with image-derived in-
put functions from the higher dose (180 and 240 μg)
were used to simulate higher-dose tumor TACs. These
were compared to the measured TACs at the higher-
dose levels. TACs for higher-dose levels were also simu-
lated using a conventional linear compartmental model
fit to the low-dose measurements. The linear model was
identical to the non-linear model described here with
the exception that the antigen-antibody association rate
is independent of [Ag-Ab].
Results
Serial PET images and TAC curves
Representative serial planar images for both tracers (ad-
ministered mass of mAb 180 μg) at 24, 48, and 96 h p.i.
are shown in Fig. 2 (left). There is sufficient contrast for
both the 124I- and 89Zr-labeled antibody as early as 24 h
p.i to allow clear delineation of the s.c. LNCaP tumors
present in the lower flank of the mice. The estimated
average tumor-to-blood activity concentration ratios for
the 89Zr- and 124I-J591 at 24 h p.i are 1.5 and 2.4, re-
spectively. At 96 h p.i., the average tumor-to-blood ratios
increased to approximately 7.7 and 8.5 for 89Zr- and
124I-J591, respectively. TACs for plasma and tumor for
each tracer are provided in Fig. 2 (right). There are
major differences in the tumor TAC between the tracers,
suggesting a difference in the in vivo biological fate of the
two PET isotopes. For 89Zr-J591, the tumor activity con-
tinuously increased from 24 to 96 h p.i., rising from ~15
to ~40 %ID/g, respectively. Conversely, tumor activity
concentration for 124I-J591 reaches a maximum uptake
in tumor of ~18 %ID/g at 24 h p.i. which persisted for
the following 24 h before dropping to ~12.5 %ID/g at
96 h p.i. Furthermore, the thyroid is clearly visible in the
124I-J591 images, indicating that significant de-iodination
occurred in vivo. These characteristics of radiolabeled
J591 tracer in mice carrying s.c. LNCaP are similar to
those in our previously published reports for 89Zr-DFO-
J591 [26] and 131I-J591 [27] investigated in the same
mouse model.
Comparison of 89Zr- and 124I-J591 PET kinetic model
parameter estimates
Estimates of four different kinetic model parameters
were derived for the two different tracers: total LNCaP
PSMA antigen concentration (Agtotal), association rate con-
stant (ka), internalization rate (k3,2), and efflux rate (k0.3).
Parameter estimates are provided as average ± standard de-
viation with their appropriate units for the 124I (n = 7) and
89Zr (n = 5) groups. Representative TACs generated from
model fits are shown overlayed on the relevant measured
data in Fig. 3. Root-mean-squared error calculated for the
fitted TACs ranged from 0.31 to 1.14 %ID/g for 124I-J591
and from 1.06 to 7.18 %ID/g for 89Zr-J591. The [Agtotal]
was found to be almost identical for both radiolabeled
antibodies (124I 1.3 ± 0.2 μM, 89Zr 1.2 ± 0.2 μM). This
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result was expected, as there were no apparent differences
in Bmax between the two tracers in vitro. These values
are also consistent with previously published in vitro
results, which predict an antigen concentration of be-
tween 1.00 and 1.33 μM [24], and serve to validate in
part our modeling process. The tumor xenografts
were within the same volume range for all groups of
animals. Secondly, although the association rate constant
(ka) was also found to be significantly higher (p < 0.05) for
124I- than for 89Zr-J591, with values of 7.0 × 107 ± 1.5 × 107
and 4.4 × 107 ± 1.9 × 107 M−1h−1, respectively, the magni-
tude of the difference is less than twofold. We believe this
indicates that uptake dynamics were not drastically affected
by the choice of radiolabel. Thirdly, the internalization kin-
etics were compared and the difference between internal-
ization rates was not significant (124I 242 ± 125 M−1h−1,
89Zr 270 ± 148 M−1h−1). For the 180-μg-dose data, the aver-
age maximum internalization rate is 1.2 × 1013 molecules
per gram of tissue per hour. Using an estimate of 108
LNCaP cells per gram, we calculate that this is equal to
1.2 × 105 molecules internalized per cell per hour or 20 %
of the estimated 600,000 sites per cell. This is in agreement
with our hypothesis that the antibody delivery mechanism
can be loaded with different cargo types yet retain
the same delivery kinetics.
Finally, the parameter with the greatest difference
between the iodine- and zirconium-labeled experiments
was the efflux value, with 124I-J591 having a very significant
ninefold higher efflux rate of the radiolabel than that of
89Zr-J591 (p < 0.0000005) (Fig. 4).
Estimation of accumulated activity in separate tumor
compartments and targeting index
From the fitted tumor and plasma TACs, the time inte-
grals of the respective activity concentrations were cal-
culated. The targeting index was defined as the ratio of
the time-integrated activity concentration in the tumor
to the time-integrated activity concentration in plasma.
This serves as a metric of the exposure of the tumor to
a therapeutic radionuclide or drug versus non-tumor
systemic exposure. Targeting indices were calculated
from the observed data and plotted against the adminis-
tered antibody dose, indicating that the targeting index
is much lower at higher antibody doses. Using “best-fit”
parameters derived from kinetic modeling of tracer
89Zr-J591 (i.e., 60 μg/mouse), the TACs for higher doses
up to 2000 μg of 89Zr-J591 were obtained to determine
the correlation between predicted TACs generated via
kinetic modeling and empirically measured TACs. The
targeting indices calculated using curves generated with
the non-linear compartment model are shown in Fig. 5
and show a very close concordance with the observed
data. The maximum targeting index for the experimental
Ab levels was 3.4 at the lowest dose of 60 μg. Predicted
Fig. 2 Representative serial PET images at 24, 48, and 96 h p.i. of mice bearing s.c. LNCaP tumors imaged with either 89Zr-J591 (a) or 124I-J591 (b).
The tumor is indicated in all of the transverse and coronal images by a white arrow. The thyroid is indicated by the red arrow in the coronal 124I-J591
images only. Time-activity curves for tumor and blood corresponding to the images in a and b of 89Zr- (c) and 124I-J591 (d) imaged mice
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targeting index at a 2000-μg dose of 89Zr-J591 was 0.80
compared to the observed targeting index for that dose of
0.78 ± 0.10 (mean ± standard error). Analogous predicted
TACs generated using a compartment model with a linear
unimolecular binding component (i.e., not dependent on
antigen concentration) were also generated. Corresponding
targeting indices were calculated for the higher doses based
on the assumption of a linear Ag-Ab binding component.
As can be seen, the predicted targeting indices using a con-
ventional linear model, particularly for the very high satur-
ating or near-saturating doses, do not agree well with the
observed data. The linear model here predicts a constant,
dose-independent targeting index. The antigenic sites
are saturated at high antibody doses, and further in-
creases in the administered dose do not produce cor-
responding increases in targeting index. Rather, the
reverse is true, with higher doses generally yielding
lower targeting indices.
The compartmental model separates uptake into sur-
face and internalized compartments. Internalized activity
can thus be extracted from the total tumor imaging
signal. In Fig. 6, simulated internalized activities using
actual plasma TACs and fitted model parameters are
shown for both the iodine- and zirconium-labeled anti-
bodies. Early time points show similarity in the activity
in the internalized compartment for both radiolabeled
forms of J591. The difference in internalized compart-
ment activity does not exceed 1 %ID/g until about 24 h
p.i. As can be seen, due to the residualizing nature of
the radiometal, activity in the internalized compartment
persists at a high level relative to that for iodinated anti-
body. 124I-J591 shows signs of efflux of activity from the
internalized compartment with activity peaking at 40.5 h
p.i. At 96 h p.i., activity in the internalized compartment
for 89Zr-J591 is predicted to be approximately 2.7 times
higher than that for 124I-J591.
Fig. 3 Representative data for 60-μg dose of 89Zr-J591 (top) and 180-μg dose of 124I-J591 (bottom). Model-fitted TACs shown over measured
experimental data
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Discussion
Two different radiolabeled forms of the same mAb were
injected into groups of LNCaP tumor-bearing mice and
their tumor uptake kinetics compared by serial PET im-
aging: J591, a specific PSMA-targeted antibody that is
known to be internalized after binding to extracellular
antigen, labeled with either 89Zr, a residualizing PET
isotope, or 124I, a non-residualizing PET isotope.
This work demonstrates the development and use of a
non-linear compartment model to quantitate the in vivo
characteristics of an administered radiolabeled antibody
in a pre-clinical murine cancer therapy trial as a func-
tion of the antibody dose. Values for biologically relevant
parameters, namely, antibody-antigen association rate,
total antigen concentration in tumor, internalization rate,
and clearance rate from the tumor, were estimated using
the model. Serial PET data from multiple scans repeated
on the same animals up to 96 h p.i. were successfully fit to
the proposed model and demonstrated a marked differ-
ence in clearance for the two radioisotopes used. This
will inform future development of radioimmunotherapy
based on this antibody model; for example, estimation of
optimum Ab-administered mass on a patient-specific basis
during treatment planning. The model also enabled the
evaluation of the “residence” of the radioisotope in the
tumor, particularly in the internalized compartment. Quan-
titative imaging in this pre-clinical model has proven to be
a useful tool in evaluating both the targeting and residence
of radioimmunotherapy agents and thus their predicted
efficacy while still in a pre-clinical phase.
Binding and internalization of J591 to PSMA-expressing
tumor xenografts were similar when radiolabeled with
either 89Zr or 124I. The similarity in binding parameters
for these two radioisotopes suggests that radioisotope
selection does not affect the delivery of the antibody
to target cells. The similar binding and internalization
rates support the concept of antibody as a targeting
Fig. 5 Targeting index defined as ratio of integral of activity at tumor to integral of activity in plasma as a function of dose. Projected targeting
indices based on low-dose parameter estimates are shown for both our non-linear Ag-Ab binding model and for a conventional linear model
Fig. 4 Comparison of efflux rates for 124I- and 89Zr-labeled antibody
(shown as average ± standard error of the mean; n = 7 and n = 5,
respectively). There is an approximately ninefold difference in rates
for the two radiolabeled forms
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vehicle to which different payloads can be attached. Using
this paradigm, an antibody system could be investigated
and characterized in vivo using a positron-emitting radio-
isotope payload and PET imaging. An alternative radioiso-
tope more suitable for therapy could then be substituted.
While the in vivo fate of the particular payload (e.g., a dif-
ferent radioisotope) would still have to be characterized
experimentally, we may not need to re-evaluate specific-
ally the delivery and uptake kinetics of the antibody. This
could potentially be extended to antibody-drug conjugates
as well; additional experiments would be warranted to
determine if the compartmental model were accurate for
a particular antibody-drug conjugate (e.g., by comparing
the cytotoxic drug residence to that of a surrogate
radioisotope).
The difference in efflux of radioactivity from tumor
between the two radiolabeled forms of mAb may be
attributable to differential biological fate of the radio-
isotopes intracellularly. The large difference in the ef-
flux rate is consistent with residualization of zirconium,
but not of the iodine, in the target cells. Metal ions
such as zirconium are known to be sequestered in
cells. In this case, the identity of the zirconium-
associated adduct that is sequestered has yet to be in-
vestigated. Iodine, on the other hand, is known not to
be residualized and exits the cell and returns to the
circulation much more rapidly. The appearance of the
thyroid in the 124I antibody images is very likely
attributable to the in vivo de-iodination of the anti-
body and physiologic avid accumulation of the result-
ing free iodine (i.e., iodide) in the thyroid.
With appropriate values estimated empirically for the
free parameters, our model can be used to simulate
tumor TACs under different conditions. We generated
simulated TACs at the different dose levels for which we
collected the mouse data. The non-linear model much
more accurately predicted TACs at different dose levels
than did a conventional (i.e., linear) model, which does
not take into account the saturable nature of antigen-
antibody binding. As previously stated, analysis of in-
ternalization and residence of activity at the tumor can
have implications for radioimmunotherapy. In this case,
the residualizing nature of radiometals resulted in zirco-
nium remaining internalized and thus accumulating to
higher activities for longer periods of time than did iod-
ine. This directly affects the absorbed dose to the tumor,
with potential radiobiological implications such as the
proximity of the radionuclide to the radiosensitive cell
nucleus. Also, estimation of the internalized fraction can
be of significant importance to the prediction of efficacy
of a particular antibody-drug conjugate dose, as the
antibody-drug conjugate is frequently administered in a
pro-drug form and activated upon internalization. The
concentration of the drug in the internalized compart-
ment may be more indicative of therapeutic efficacy than
the total concentration in the tumor.
Fig. 6 Simulated rate of surface binding and internalization for 180-μg Ab doses of 124I- and 89Zr-J591. Surface binding decreases with time, but
activity detected at tumor remains high due to internalized Ab-Ag. Differences in total observed tumor activity can be explained primarily by
differences in the internalized portion of injected dose while surface binding curves remain nearly identical across radiolabels
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Conclusions
We have successfully applied a non-linear compartment
model to pre-clinical PET data of in vivo tumor uptake
of a targeted antibody. Using the model, we have quantita-
tively assessed parameters of biological and clinical signifi-
cance including antigen concentration, internalization
rates, and efflux rates of antibody from tumor. We have
demonstrated that the kinetics of two radiolabeled forms
of the humanized mAb J591, 124I- and 89Zr-J591, do
not differ drastically in terms of initial uptake. We have
shown, however, that there is a large difference in residence
time of the PET imaging signal, likely due to internalization
and subsequent residualization of the 89Zr label versus
rapid efflux of the 124I label. We found that our non-linear
compartment model performed well in predicting the tar-
geting index at higher doses and was far more appropriate
than a linear compartment model. This has important
implications for radioimmunotherapy dose optimization,
especially when using lower doses or diagnostic surrogates
for patient-specific dose planning.
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